Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

849 United States sites

369 India sites

242 United Kingdom sites

167 Canada sites

145 Italy sites

118 Turkey sites

113 Greece sites

102 France sites

97 Spain sites

49 South Africa sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult participants with severe sickle cell disease (SCD).

Locations

817 United States sites

135 Canada sites

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.

Locations

597 United States sites

95 Canada sites

52 Lebanon sites

Age

12 Years - 65 Years

Phase

Phase 2

LEARN MORE
A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia

Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.

Locations

204 United States sites

51 Canada site

Age

> 18 Years

Phase

Phase 1/Phase 2

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

2286 United States sites

311 United Kingdom sites

215 Spain sites

214 France sites

171 Italy site

169 Greece sites

129 Canada sites

90 Oman sites

86 Germany sites

85 Lebanon sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.

Locations

987 United States sites

235 Spain sites

188 Belgium sites

141 Brazil site

141 Colombia site

141 Germany site

141 India site

141 Italy site

141 United Kingdom site

94 Canada sites

94 Lebanon sites

94 Turkey sites

47 Oman sites

47 Switzerland sites

47 France sites

Age

6 Months - 17 Years

Phase

Phase 2

LEARN MORE
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease

This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).

Locations

246 United States sites

125 Canada sites

Age

2 Years - 25 Years

Phase

Phase 2

LEARN MORE
A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)

The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor.

Locations

65 Canada sites

Age

1 Year - 19 Years

Phase

Phase 2

LEARN MORE
Measures of Respiratory Health

The Lung Clearance Index, measured by multiple breath washout, is a measure of lung function that is considered a research tool in Canada as the device used to measure it is not approved by Health Canada.

Locations

60 Canada sites

Age

30 Months - 30 Years

LEARN MORE